Trial Profile
A Study to Evaluate Whether Pretreatment Spectral-Domain Optical Coherence Tomographic (SD-OCT) Features are Associated With Visual Prognosis after Treatment For Idiopathic Subfoveal Choroidal Neovascularization With Intravitreal Ranibizumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Jun 2016
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Choroidal neovascularisation
- Focus Therapeutic Use
- 09 Jun 2016 New trial record